1. Nyman H.A., Jorgenson J.A., Slawson M.H. Workplace contamination with
antineoplastic agents in a new cancer hospital using a closed-system drug transfer device.
Hospital Pharmacy, 2007, 42.3: 219-225.
2. Wick, C., Slawson, M. H., Jorgenson, J. A., Tyler, L. S. Using a closed-system
protective device to reduce personnel exposure to antineoplastic agents. American Journal of
Health-System Pharmacy, 2003, 60.22: 2314-2320.
3. Castiglia L., et al. Evaluation of occupational exposure to antiblastic drugs in an
Italian hospital oncological department. Journal of occupational health, 2008, 50.1: 48-56.
4. Ndaw S., Denis F., Marsan P., Rémy A., Robert A. Professional exposure of hospital healthcare
staff to cytotoxic medicines. 2018. Références En Santé Au Travail
(Occupational Health References)— No. 154
5. Connor T.H., Zock M.D., Snow A.H. Surface wipe sampling for antineoplastic
(chemotherapy) and other hazardous drug residue in healthcare settings: methodology and
recommendations. Journal of occupational and environmental hygiene, 2016, 13.9:
658-667.
6. ALERT, NIOSH. Preventing occupational exposures to antineoplastic and other
hazardous drugs in health care settings. NIOSH, Pub. 2004, 165.
7. Yuki M., Sekine S., Takase K., Ishida T., Sessink P. J. Exposure of family members
to antineoplastic drugs via excreta of treated cancer patients. Journal of Oncology Pharmacy
Practice, 2013, 19.3: 208-217.
8. Boiano J.M., Steege A.L., Sweeney M.H. Adherence to safe handling guidelines by
health care workers who administer antineoplastic drugs. Journal of occupational and
environmental hygiene, 2014, 11.11: 728-740.
9. Turci R, Minoia C, Sottani C, et al. Occupational exposure to antineoplastic drugs
in seven Italian hospitals: The effect of quality assurance and adherence to guidelines.
Journal of Oncology Pharmacy Practice. 2011;17(4):320-332
BD and the BD Logo are trademarks of Becton, Dickinson and Company or its affiliates.
© 2024 BD. All rights reserved. BD-120387 (06/24)